Carl June, MD of the University of Pennsylvania and colleagues announced in a recent paper that faster production of the CAR T cells improves the strength of the treatment.  The CD19 CAR T therapy has been in development for many years, launching initially in leukemia. This new therapy holds significant promise for all blood cancer[...]

Antibody Drug Conjugates (ADCs) are a new type of immunotherapy that is being developed and tested in multiple myeloma. To better understand how and why ADCs work, we first need to look at some different classifications of drugs that have traditionally been used to treat multiple myeloma. Chemotherapy Chemotherapy has been used to treat multiple[...]

Empliciti (elotuzumab) was approved yesterday by the FDA for use with pomalidomide and dexamethasone in relapsed myeloma, according to a press release by Bristol-Myers Squibb. The combination was approved for patients who relapsed after two prior treatments including lenalidomide and a proteasome inhibitor.  The immunotherapy was tested in a study called the ELOQUENT-3 trial. In[...]

Originally written by myeloma patient and advocate Cindy Chmielewski. Recently, I had the privilege to travel to New Orleans to attend the American Association for Cancer Research’s (AACR) Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved Conference. I was part of the Scientist-Survivor Program (SSP) – a program I would highly recommend to anyone[...]

A new pathway to stop myeloma progression is being studied with a new drug, according to a recent report by UK multiple myeloma specialists.  A pathway that helps myeloma cells survive, called nuclear factor (NF)‐κB, is activated in all cases of multiple myeloma. Many companies have tried to target this pathway over the last 30[...]

For all purchases made between October 29 – November 2, Amazon Smile will give 5% of your purchase back to the Myeloma Crowd. Visit smile.amazon.com today, choose the “CrowdCare Foundation” as your designated foundation, and start shopping! This offer only lasts for Myeloma Awareness Month, so sign up today and make a difference. What is AmazonSmile?[...]

Recent Phase II/III study results by Celgene showed that Revlimid (lenalidomide) extended time to disease progression from smoldering myeloma to active myeloma for high-risk smoldering myeloma patients. Smoldering myeloma patients may never progress to active myeloma, so the question they and their doctors ask is “Do I need treatment?” For those who have high-risk smoldering[...]

[...]

As seen on PR Newswire The Myeloma Crowd™, a division of the CrowdCare Foundation, today announced the launch of HealthTree®, a new online tool to help Multiple Myeloma patients find their best myeloma treatments and accelerate research toward a cure. HealthTree is the first resource of its kind where patients can track their myeloma lab values across[...]

A recent analysis of relapsed or refractory multiple myeloma clinical trials concluded that combination and triple regimens are effective first-line treatment strategies. Xian-Wu Luo and a group of fellow Chinese researchers from Wuhan University performed an updated network meta-analysis because of the complex biological makeup of myeloma. They studied results from 24 clinical trials to[...]